(NASDAQ: HBIO) Harvard Bioscience's forecast annual revenue growth rate of 5.84% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 6.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.87%.
Harvard Bioscience's revenue in 2024 is $112,250,000.On average, 2 Wall Street analysts forecast HBIO's revenue for 2024 to be $5,155,835,771, with the lowest HBIO revenue forecast at $5,060,357,331, and the highest HBIO revenue forecast at $5,251,314,211.
In 2025, HBIO is forecast to generate $5,858,904,285 in revenue, with the lowest revenue forecast at $5,858,904,285 and the highest revenue forecast at $5,858,904,285.